AbbVie Inc.

Company facts

Industry

Pharmaceutical Preparations

Headquarters

North Chicago, Illinois

Most recent report

8-K, filed Sep 3, 2026

Incorporated

Delaware

Filings on record

1,000+ filings

On EDGAR

CIK 1551152

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Jun 2026 10-Q

SECSift found 2 of 10 sections worth reading, with 7 positive, 7 notable, and 6 negative flags.

• Financial Statements (Item 1)

  Core financials with company-specific numbers: massive contingent liabilities, new acquisition, and revenue shifts.
  Notable

  • Proposed $10.9B acquisition of Apogee in June 2026, funded partly by new $10B term loan.
  • In June 2026, AbbVie reached an agreement to resolve substantially all US ALCL lawsuits, removing a key uncertainty.
  Negative

  • Three U.S. wholesalers accounted for 82% of receivables at June 30, 2026, up from 78% at March 31.

• Management's Discussion (Item 2)

  Dense MD&A with detailed product revenue, liquidity actions, pipeline, and pricing risk.
  Positive

  • Worldwide net revenues $32.0B H1 2026, up 11% reported, 10% constant currency.
  • Operating earnings $10.4B H1 2026.
  • Cash flows from operations $7.3B H1 2026, up from $6.8B prior year.
  • Skyrizi total $9.988B H1 2026, up 27.3% reported, 26.3% constant currency.
  • Rinvoq total $4.644B H1 2026, up 24% reported, 22% constant currency.
  • Gross margin 75% of net revenues in Q2 2026 vs 72% in Q2 2025.
  • Repurchased 5M shares for $1.1B in H1 2026.
  Notable

  • Botox selected for Medicare Parts B and D price negotiation starting 2028.
  • Vyalev revenue >100% growth, $457M in H1 2026.
  • $650M upfront charge for RemeGen license in H1 2026.
  • $8.0B aggregate principal of senior notes issued in H1 2026.
  • $10.0B 364-day term loan facility entered after June 30 for Apogee acquisition.
  Negative

  • Epkinly Phase 3 trial did not show statistically significant OS improvement in R/R DLBCL.
  • Humira revenue $1.444B H1 2026, down 37.2% reported due to biosimilar competition.
  • Imbruvica global revenue down 29% in Q2 2026 due to unfavorable pricing and demand.
  • Juvederm Collection revenue down 6.6% constant currency in Q2 2026 on lower demand.
  • Contingent consideration charge $3.9B in H1 2026 (non-cash) largely from higher Skyrizi estimates.

What changed: Jun 2026 vs. Mar 2026

About 9% of ABBV's Jun 2026 10-Q is new information. 28 paragraphs were added, 119 changed, and 12 removed. Below are the most important lines SECSift identified.

• Item 2 56
• Item 1 54
• Item 4 2
• Item 5 1